Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Tian ShenShanhua ZhengLei GengZhengtao LiuJun XuBingyi LinJunjie QianShushen ZhenPublished in: Technology in cancer research & treatment (2021)
Anti-PD-1 antibody camrelizumab had a manageable safety profile in patients with advanced BTC. This initial assessment of camrelizumab monotherapy provides effective evidence for patients with refractory BTC in biomarker-unselected patients.